Register for this Live Webinar.
In the race to bring new oncology therapies to market, patient selection is more critical than ever. With narrow windows of exclusivity and mounting competitive pressure, biotech sponsors are rethinking their clinical development strategies -starting with smarter trial enrollment.
This live panel discussion featuring Dr. Brian Barnett and other leading industry experts will explore how recent advances in biomarker science and companion diagnostics are reshaping oncology trials. From Phase I onward, sponsors now have powerful tools to enrich trials with the patients most likely to benefit, driving faster timelines, greater efficiency, and better outcomes.
Join this session to learn:
- How emerging diagnostic technologies are informing early-stage patient selection
- Real-world strategies for enrichment that improve trial efficiency and reduce risk
- Best practices for integrating biomarkers and companion diagnostics into clinical design
- Insights from oncology development experts on what’s working—and what’s next—in a rapidly evolving therapeutic landscape
Whether you’re leading clinical development, overseeing biomarker strategy, or seeking ways to improve speed-to-data in oncology trials, this is a must attend conversation.
Offered Free by: Allucent
See All Resources from: Allucent
